Qucosa
Not a member yet
63150 research outputs found
Sort by
Studienführer ... / Hochschule für Musik und Theater „Felix Mendelssohn Bartholdy” Leipzig
No full textStudienführer, Vorlesungsverzeichnis ... / Hochschule für Musik und Theater „Felix Mendelssohn Bartholdy” Leipzig
No full textBone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure
No full textAim:
To assess bone status expressed as hip bone mineral density (BMD) in men with heart failure (HF).
Methods and results:
A total of 141 male patients with HF underwent dual energy X-ray absorptiometry to assess their BMD. We analysed markers of bone metabolism. Patients were classified as lower versus higher BMD according to the median hip BMD (median = 1.162 g/cm2). Survival was assessed over 8 years of follow-up. Patients with lower BMD were older (71 ± 10 vs. 66 ± 9 years, p = 0.004), more likely to be sarcopenic (37% vs. 7%, p < 0.001) and to have lower peak oxygen consumption (absolute peak VO2 1373 ± 480 vs. 1676 ± 447 ml/min, p < 0.001), had higher osteoprotegerin and osteocalcin levels (both p < 0.05) compared to patients with higher BMD. Among 47 patients with repeated BMD assessments, a significant reduction in BMD was noted over 30 months of follow-up. In multivariate logistic regression analysis, serum osteocalcin remained independently related with lower BMD (odds ratio [OR] 1.738, 95% confidence interval [CI] 1.136–2.660, p = 0.011). Hip BMD and serum osteoprotegerin were independent predictors of impaired survival on Cox proportional hazard analysis (hazard ratio [HR] 0.069, 95% CI 0.011–0.444, p = 0.005, and HR 0.638, 95% CI 0.472–0.864, p = 0.004, respectively).
Conclusions:
Patients with HF lose BMD over time. Markers of bone turnover can help in identifying patients at risk with osteocalcin being an independent marker of lower hip BMD and osteoprotegerin an independent predictor of death. HF patients with increased osteocalcin and osteoprotegerin may benefit from BMD assessment as manifest osteoporosis seems to be too late for clinically meaningful intervention in HF
Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study
No full textBackground: Post-transplant lymphoproliferative disorders (PTLD) are
heterogeneous lymphoid disorders ranging from indolent polyclonal
proliferations to aggressive lymphomas that can arise after solid organ
transplantation (SOT) and allogeneic hematopoietic transplantation (allo-HSCT).
Methods: In this multi-center retrospective study, we compare patient
characteristics, therapies, and outcomes of PTLD after allo-HSCT and SOT.
Twenty-five patients (15 after allo-HSCT and 10 after SOT) were identified who
developed PTLD between 2008 and 2022.
Results: Median age (57 years; range, 29-74 years) and baseline characteristics
were comparable between the two groups (allo-HSCT vs SOT), but median onset
of PTLD was markedly shorter after allo-HSCT (2 months vs. 99 months,
P<0.001). Treatment regimens were heterogeneous, with reduction of
immunosuppression in combination with rituximab being the most common
first-line treatment strategy in both cohorts (allo-HSCT: 66%; SOT: 80%). The
overall response rate was lower in the allo-HSCT (67%) as compared to the SOT
group (100%). Consequently, the overall survival (OS) trended towards a worse
outcome for the allo-HSCT group (1-year OS: 54% vs. 78%; P=0.58). We
identified PTLD onset ≤150 days in the allo-HSCT (P=0.046) and ECOG >2 in
the SOT group (P=0.03) as prognostic factors for lower OS.
Conclusion: PTLD cases present heterogeneously and pose unique challenges
after both types of allogeneic transplantation
Application of Artificial Intelligence in Education and Research at the Faculty of Forestry, University of Sopron
No full text
Biographische Forschungspraxis in den Jüdischen Studien: ein Plädoyer für mehr Methodenbewusstsein
No full textUnternehmenskultur im Industriedorf: Die Papierfabriken Kübler & Niethammer in Sachsen (1856–1956)
No full textÜberarbeitete Fassung der Dissertation, Technische Universität Dresden, 201
Regulation of CD163 Receptor in Patients with Abdominal Aortic Aneurysm and Associations with Antioxidant Enzymes HO-1 and NQO1
No full textRed blood cells are found within the abdominal aortic aneurysm (AAA), in the intraluminal thrombus (ILT), and in neovessels. Hemolysis promotes aortic degeneration, e.g., by heme-induced reactive oxygen species formation. To reduce its toxicity, hemoglobin is endocytosed by the CD163 receptor and heme is degraded by heme oxygenase-1 (HO-1). A soluble form (sCD163) is discussed as an inflammatory biomarker representing the activation of monocytes and macrophages. HO-1 and NAD(P)H quinone dehydrogenase 1 (NQO1) are antioxidant genes that are induced by the Nrf2 transcription factor, but their regulation in AAA is only poorly understood. The aim of the present study was to analyze linkages between CD163, Nrf2, HO-1, and NQO1 and to clarify if plasma sCD163 has diagnostic and risk stratification potential. Soluble CD163 was 1.3-fold (p = 0.015) higher in AAA compared to patients without arterial disease. The difference remained significant after adjusting for age and sex. sCD163 correlated with the thickness of the ILT (rs = 0.26; p = 0.02) but not with the AAA diameter or volume. A high aneurysmal CD163 mRNA was connected to increases in NQO1, HMOX1, and Nrf2 mRNA. Further studies are needed to analyze the modulation of the CD163/HO-1/NQO1 pathway with the overall goal of minimizing the detrimental effects of hemolysis